The presence of human papillomavirus type 16/18 DNA in blood circulation may act as a risk marker of lung cancer in Taiwan

被引:68
作者
Chiou, HL
Wu, MF
Liaw, YC
Cheng, YW
Wong, RH
Chen, CY
Lee, H
机构
[1] Chung Shan Med Univ, Inst Toxicol, Taichung 402, Taiwan
[2] Chung Shan Med Univ, Sch Med Technol, Taichung 402, Taiwan
[3] Chung Shan Med Univ, Inst Med, Taichung 402, Taiwan
[4] Chung Shan Med Univ, Lung Canc Res Ctr, Taichung 402, Taiwan
[5] Chung Shan Med Univ, Dept Publ Hlth, Taichung 402, Taiwan
[6] Chung Shan Med Univ Hosp, Dept Internal Med, Taichung, Taiwan
[7] Taichung Vet Gen Hosp, Dept Thorac Surg, Taichung, Taiwan
关键词
human papillomavirus; blood circulation; cancerous tissue; lung cancer;
D O I
10.1002/cncr.11191
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BACKGROUND. Lung cancer is the leading cause of cancer death in Taiwan, and the paucity of dependable risk markers has impeded the early management of lung cancer. An association of human papillomavirus (HPV) 16/18 infection with lung cancer among nonsmoking Taiwanese women was revealed in our previous study. METHODS. Nested PCR was employed to detect HPV 16/18 DNA in the blood circulation of 149 lung cancer patients and 174 noncancer controls. In addition, correlation of prevalence of HPV DNA between the blood circulation and lung tumor tissue was compared from 70 sets of paired tumor tissues and peripheral blood samples available. RESULTS. The results showed that the prevalence rate of HPV 16/18 in the blood circulation of lung cancer cases was significantly higher than that of noncancer controls (47.7% vs. 12.6% for HPV 16, P < 0.0001; 30.9% vs. 5.2% for HPV 18, P < 0.0001). A significantly higher HPV 16 prevalence was detected in female lung cancer patients than that of male (57.6% vs. 41.1%, P = 0.048), as well as in cases with tumor Stages III/IV than those with tumor Stages I/II (54.6% vs. 29.3%, P = 0.006). After adjusting the effects of age, gender, and smoking status, a 6.5-fold greater risk of lung cancer was demonstrated for those subjects with HPV Type 16 positive (95% CI 3.7-11.3, P < 0.0001), a 9.2-fold for HPV Type 18 positive (95% CI 4.2-20.2, P < 0.0001), and a 75.7-fold greatest risk for those with both HPV Type 16 and 18 positive (95% CI 9.8-582.1, P < 0.0001). These results suggested that the presence of HPV DNA in the blood CONCLUSIONS. circulation may serve as a feasible risk marker of lung cancer. (C) 2003 American Cancer Society..
引用
收藏
页码:1558 / 1563
页数:6
相关论文
共 18 条
  • [1] Capone RB, 2000, CLIN CANCER RES, V6, P4171
  • [2] Cheng YW, 2001, CANCER RES, V61, P2799
  • [3] Dong SM, 2002, CANCER EPIDEM BIOMAR, V11, P3
  • [4] The human papillomavirus type 16 E7 oncogene is required for the productive stage of the viral life cycle
    Flores, ER
    Allen-Hoffmann, BL
    Lee, D
    Lambert, PF
    [J]. JOURNAL OF VIROLOGY, 2000, 74 (14) : 6622 - 6631
  • [5] Forgacs Eva, 2001, Pathology and Oncology Research, V7, P6
  • [6] Human papillomavirus DNA in squamous cell carcinoma of the lung
    Hirayasu, T
    Iwamasa, T
    Kamada, Y
    Koyanagi, Y
    Usuda, H
    Genka, K
    [J]. JOURNAL OF CLINICAL PATHOLOGY, 1996, 49 (10) : 810 - 817
  • [7] Viral load of human papilloma virus 16 as a determinant for development of cervical carcinoma in situ: a nested case-control study
    Josefsson, AM
    Magnusson, PKE
    Ylitalo, N
    Sorensen, P
    Qwarforth-Tubbin, P
    Andersen, PK
    Melbye, M
    Adami, HO
    Gyllensten, UB
    [J]. LANCET, 2000, 355 (9222) : 2189 - 2193
  • [8] Somatic mutation screening: Identification of individuals harboring K-ras mutations with the use of plasma DNA
    Kopreski, MS
    Benko, FA
    Borys, DJ
    Khan, A
    McGarrity, TJ
    Gocke, CD
    [J]. JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2000, 92 (11) : 918 - 923
  • [9] Low incidence of HPV DNA in sera of pretreatment cervical cancer patients
    Liu, VWS
    Tsang, P
    Yip, A
    Ng, TY
    Wong, LC
    Ngan, HYS
    [J]. GYNECOLOGIC ONCOLOGY, 2001, 82 (02) : 269 - 272
  • [10] Lo YMD, 1999, CANCER RES, V59, P1188